K. Trunzer

发表

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

F. Cappuzzo, W. Brugger, N. Triller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)

A. Zelenetz, M. Kaminski, I. Flinn, 2013 .

AnalysisofDermatologic Events inVemurafenib-TreatedPatients WithMelanoma

Patrícia, A. Hauschild, D. Schadendorf, 2013 .

Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.

A. Hauschild, D. Schadendorf, K. Flaherty, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

J. V. van Dongen, G. Fingerle-Rowson, M. Hallek, 2019, Blood.

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

F. Bosch, R. Foà, S. Robson, 2019, Leukemia.

Chronic lymphocytic leukemia Obinutuzumab plus fl udarabine and cyclophosphamide in previously untreated , fi t patients with chronic lymphocytic leukemia : a subgroup analysis of the GREEN study

F. Bosch, R. Foà, S. Robson, 2019 .

Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

A. Hauschild, D. Schadendorf, M. Lacouture, 2013, The oncologist.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Dirk Schadendorf, Alessandro Testori, Axel Hauschild, 2014, The Lancet. Oncology.

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

Qiongqing Wang, K. Trunzer, Richard J Lee, 2012, Cancer research.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

K. Flaherty, J. Reis-Filho, Qiongqing Wang, 2012, The New England journal of medicine.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens

F. Cappuzzo, L. Bubendorf, K. Kerr, 2020, Cancer cytopathology.

mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses

S. Novello, R. Dziadziuszko, J. Mazières, 2019, Journal of Thoracic Oncology.

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

R. Dziadziuszko, J. Mazières, K. Trunzer, 2022, ESMO open.

Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts).

K. Flaherty, J. Sosman, A. Ribas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

K. Syrigos, Jinming Yu, K. Trunzer, 2021, Journal for ImmunoTherapy of Cancer.

Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2012 .

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

T. Manshouri, S. Verstovsek, K. Trunzer, 2023, Haematologica.

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

F. Bosch, R. Foà, S. Robson, 2017 .

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

F. Cappuzzo, W. Brugger, N. Triller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.